Latest Health News

Page 1 of 271
Resonance Health delivered a $1.5 million profit and positive operating cash flow in every quarter of FY26, while raising $6 million to accelerate three growth programmes. The challenge is replacing a MASH trial that generated 48% of last year’s revenue.
Ada Torres
Ada Torres
19 Nov 2026
Nufarm has delivered a sharp FY26 recovery in underlying earnings and cash generation, with leverage falling to 2.0 times despite a 7% revenue decline. The statutory loss, no ordinary dividend and ongoing restructuring show the turnaround remains unfinished.
Ada Torres
Ada Torres
19 Nov 2026
Dotz Nano has repriced its A$2 million placement after CEO and director Nati Harpaz resigned for health reasons, increasing the proposed share issue while adding more generous attaching options. The company has also clarified that its September quarterly report described commitments as a completed raise even though no shares or funds had then changed hands.
Victor Sage
Victor Sage
18 Nov 2026
Black Bear Minerals has secured MSHA approval for alternative mine rescue arrangements at its Shafter Silver Project in Texas, opening a compliant pathway to underground exploration. The work is intended to support resource validation, a maiden JORC estimate and early mine planning, but exploration has not yet begun.
Maxwell Dee
Maxwell Dee
18 Nov 2026
Xenitra has secured a three-year strategic cooperation agreement with JD Health carrying a non-binding A$100 million sales target across prescription medicines, OTC products, FSMP products and health products. The first order is expected in December, with sales targeted to begin in January 2027, but the agreement does not guarantee revenue or impose a penalty if the target is missed.
Victor Sage
Victor Sage
18 Nov 2026
North Carolina regulators have approved Duke Energy’s rate settlements, authorising billions of dollars of investment while reducing the revenue increases the utilities initially sought. New rules for large data centre customers add protection against early exits and network costs, but final revenue calculations remain outstanding.
Maxwell Dee
Maxwell Dee
17 Nov 2026
Island Pharmaceuticals is moving Galidesivir into a decisive sequence of Marburg animal studies after the FDA confirmed an Animal Rule pathway for the antiviral. The company also expects to generate prospective human data through an approved Uganda Ebola program, although approval, funding and commercial outcomes remain unresolved.
Victor Sage
Victor Sage
17 Nov 2026
Regis Healthcare delivered higher revenue, earnings and cash generation in FY26, but its new CEO is confronting a sharp funding gap across the aged care sector. The company plans to offset weaker AN-ACC support through pricing, cost reductions and further expansion.
Ada Torres
Ada Torres
17 Nov 2026
Mayne Pharma has agreed to a A$6.40-a-share cash takeover by Hungary’s Gedeon Richter, valuing the company’s equity at approximately A$604 million. The recommended scheme still depends on regulatory clearances, shareholder and court approval, and completion of Mayne’s international business sale.
Victor Sage
Victor Sage
17 Nov 2026
Catapult Sports has pushed Annualized Contract Value beyond A$200 million while lifting Management EBITDA margin to 20% in the first half of FY27. The stronger operating result came alongside a wider statutory loss, reflecting acquisition-related and other non-cash charges.
Victor Sage
Victor Sage
17 Nov 2026
Vectus Biosystems has received supportive written FDA feedback on VB0004, reducing uncertainty around the drug candidate’s manufacturing, nonclinical and planned clinical development package. The company will now incorporate the guidance into an IND application for a Phase Ib/IIa study in IPF patients in Australia.
Ada Torres
Ada Torres
16 Nov 2026
Moderna’s chief legal officer will retire in March under an agreement that provides US$1.63 million in fixed severance and up to US$8 million linked to litigation outcomes. The package also preserves her salary, benefits and equity vesting through her departure date.
Ada Torres
Ada Torres
14 Nov 2026

Browse the archive

Full archive